Top

Published in:

01-12-2012

Mouse models of breast cancer metastasis to bone

Authors: Kelsi L. Kretschmann, Alana L. Welm

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Abstract

Breast cancer frequently metastasizes to bone, where it takes a significant toll on quality of life. Models of bone metastasis are needed in order to better understand the process of bone metastasis and to develop better treatments. Here, we discuss the available mouse models for breast cancer bone metastasis and critical techniques for imaging bone metastasis in these models.

American Cancer Society. (2012). Cancer facts and figures 2012. Atlanta: American Cancer Society.

Colman, R. E. (2002). Future directions in the treatment and prevention of bone metastasis. American Journal of Clinical Oncology, 25, S32–S38.CrossRef

Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584–593.PubMedCrossRef

Deil, I. J., Solomayer, E. F., & Bastert, G. (2000). Treatment of metastatic bone disease in breast cancer, bisphophonates. Clinical Breast Cancer, 1, 43–51.CrossRef

Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., et al. (1988). Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell, 55, 619–625.PubMedCrossRef

Guy, C. T., Webster, M. A., Schaller, M., et al. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proceedings of the National Academy of Sciences of the United States of America, 89, 10578–10582.PubMedCrossRef

Bouchard, L., Lamarre, L., Tremblay, P. T., et al. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell, 57, 931–936.PubMedCrossRef

Muller, W. J., Sinn, E., Pattengale, P. K., et al. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105–115.PubMedCrossRef

Nielsen, L. L., Discafani, C. M., Gurnan, M., et al. (1991). Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Research, 51, 3762–3767.PubMed

10.

Sinn, E., Muller, W., Pattengale, P., et al. (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell, 49, 465–475.PubMedCrossRef

11.

Goldstein, R. H., Weinberg, R. A., & Rosenblatt, M. (2010). Of mice and (wo)men: mouse models of breast cancer metastasis to bone. Journal of Bone and Mineral Research, 25, 431–436.PubMedCrossRef

12.

Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and Cellular Biology, 12, 954–961.PubMed

13.

Ichaso, N., & Dilworth, S. M. (2001). Cell transformation by the middle T-antigen of polyoma virus. Oncogene, 20, 7908–7916.PubMedCrossRef

14.

Lin, E. Y., Jones, J. G., Li, P., et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. American Journal of Pathology, 163, 2113–2126.PubMedCrossRef

15.

Fluck, M. M., & Haslam, S. Z. (1996). Mammary tumors induced by polyomavirus. Breast Cancer Research and Treatment, 39, 45–56.PubMedCrossRef

16.

Welm, A. L., Sneddon, J. B., Taylor, C., et al. (2007). The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 104, 7570–7575.PubMedCrossRef

17.

Kang, Y., Siegel, P. M., Shu, W., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3, 537–549.PubMedCrossRef

18.

Garcia, T., Jackson, A., Bachelier, R., et al. (2008). A convenient clinically relevant model of human breast cancer to bone metastasis. Clinical & Experimental Metastasis, 25, 33–42.CrossRef

19.

Tavazoie, S. F., Alarcon, C., Oskarsson, T., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147–152.PubMedCrossRef

20.

Minn, A. J., Gupta, G. P., Siegel, P. M., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436, 518–524.PubMedCrossRef

21.

Bos, P. D., Zhang, X. H., Nadal, C., et al. (2009). Genes that mediate breast cancer metastasis to brain. Nature, 459, 1005–1009.PubMedCrossRef

22.

Kakiuchi, S., Daigo, Y., Tsunoda, T., et al. (2003). Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Molecular Cancer Research, 1, 485–499.PubMed

23.

Juarez, P., & Guise, T. A. (2011). TGF-β in cancer and bone: implications for treatment of bone metastasis. Bone, 48, 23–29.PubMedCrossRef

24.

Mundy, G. R., Yoneda, T., & Hiraga, T. (2001). Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Seminars in Oncology, 28(2 Suppl 6), 35–44.PubMedCrossRef

25.

Canon, J. R., Roudier, M., Bryant, R., et al. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clinical & Experimental Metastasis, 25, 119–129.CrossRef

26.

Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147, 275–292.PubMedCrossRef

27.

Lelekakis, M., Moseley, J. M., Martin, T. J., et al. (1999). A novel orthotopic model of breast cancer metastasis to bone. Clinical & Experimental Metastasis, 17, 163–170.CrossRef

28.

Miller, F. R., Miller, B. E., & Heppner, G. H. (1983). Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor:heterogeneity in phenotypic stability. Invasion and Metastasis, 3, 22–31.

29.

DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer-balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, 9, 212.PubMedCrossRef

30.

Kuperwasser, C., Chavarria, T., Wu, M., et al. (2004). Reconstitution of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences of the United States of America, 101, 4966–4972.PubMedCrossRef

31.

Kuperwasser, C., Dessain, S., Bierbaum, B. E., et al. (2005). A mouse model of human breast cancer metastasis to human bone. Cancer Research, 65, 6130–6138.PubMedCrossRef

32.

Moreau, J. E., Anderson, K., Mauney, J. R., et al. (2007). Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Research, 67, 10304–10308.PubMedCrossRef

33.

DeRose, Y. S., Wang, G., Lin, Y. C., et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Medicine, 17, 1514–1520.PubMedCrossRef

34.

Weissleder, R., Tung, C. H., Mahmood, U., et al. (1999). In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology, 17, 375–378.PubMedCrossRef

35.

Henriquez, N. V., van Overveld, P. G., Que, I., et al. (2007). Advances in optical imaging and novel systems for cancer metastasis research. Clinical & Experimental Metastasis, 24, 699–705.CrossRef

36.

Serganova, I., Moroz, E., Vider, J., et al. (2009). Multimodality imaging of TGFbeta signaling in breast cancer metastases. The FASEB Journal, 23, 2662–2672.CrossRef

37.

Korpal, M., Yan, J., Lu, X., et al. (2009). Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nature Medicine, 15(8), 960–966.PubMedCrossRef

Title: Mouse models of breast cancer metastasis to bone
Authors: Kelsi L. Kretschmann
Alana L. Welm
Publication date: 01-12-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9378-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2012

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny

Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer

Genomics screens for metastasis genes

The role of FOXP3 in the development and metastatic spread of breast cancer

MicroRNA control of epithelial–mesenchymal transition and metastasis

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer